Janux Therapeutics (NASDAQ:JANX) Receives Outperform Rating from William Blair

Janux Therapeutics (NASDAQ:JANX)‘s stock had its “outperform” rating reiterated by stock analysts at William Blair in a note issued to investors on Friday,RTT News reports.

A number of other research analysts have also recently issued reports on JANX. Lifesci Capital raised Janux Therapeutics to a “strong-buy” rating in a research note on Friday, December 27th. BTIG Research boosted their price objective on Janux Therapeutics from $82.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, December 3rd. Cantor Fitzgerald restated an “overweight” rating and set a $200.00 target price on shares of Janux Therapeutics in a report on Wednesday, December 11th. UBS Group initiated coverage on shares of Janux Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $69.00 price target for the company. Finally, HC Wainwright raised their price objective on shares of Janux Therapeutics from $63.00 to $70.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $89.90.

Janux Therapeutics Stock Down 14.7 %

Janux Therapeutics stock traded down $7.49 during midday trading on Friday, hitting $43.33. 668,144 shares of the stock were exchanged, compared to its average volume of 1,266,243. The stock has a market capitalization of $2.27 billion, a PE ratio of -37.03 and a beta of 3.23. The company has a fifty day simple moving average of $54.42 and a two-hundred day simple moving average of $48.18. Janux Therapeutics has a 52 week low of $7.79 and a 52 week high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The firm had revenue of $0.44 million for the quarter, compared to the consensus estimate of $1.50 million. Janux Therapeutics’s revenue for the quarter was down 82.6% compared to the same quarter last year. As a group, equities research analysts anticipate that Janux Therapeutics will post -1.35 EPS for the current fiscal year.

Insider Activity

In related news, major shareholder Ventures Xi L.P. Avalon sold 1,843 shares of the firm’s stock in a transaction dated Thursday, October 17th. The shares were sold at an average price of $50.02, for a total value of $92,186.86. Following the completion of the sale, the insider now directly owns 6,371 shares in the company, valued at approximately $318,677.42. This trade represents a 22.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO David Alan Campbell sold 25,000 shares of Janux Therapeutics stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $53.54, for a total value of $1,338,500.00. Following the transaction, the chief executive officer now owns 282,054 shares of the company’s stock, valued at $15,101,171.16. The trade was a 8.14 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 110,177 shares of company stock worth $6,162,207 in the last quarter. Corporate insiders own 29.40% of the company’s stock.

Institutional Trading of Janux Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Amalgamated Bank increased its holdings in shares of Janux Therapeutics by 61.1% during the 2nd quarter. Amalgamated Bank now owns 970 shares of the company’s stock worth $41,000 after acquiring an additional 368 shares during the last quarter. Plato Investment Management Ltd bought a new position in Janux Therapeutics during the second quarter worth $42,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Janux Therapeutics by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock valued at $87,000 after purchasing an additional 339 shares during the last quarter. AQR Capital Management LLC bought a new position in shares of Janux Therapeutics in the second quarter valued at about $215,000. Finally, Principal Financial Group Inc. acquired a new stake in shares of Janux Therapeutics during the 2nd quarter worth about $237,000. 75.39% of the stock is owned by institutional investors and hedge funds.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.